Acute Myeloid Leukemia Clinical Trial

Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia

Summary

Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure, variable congenital abnormalities and a predisposition to malignancy, particularly acute myeloid leukemia (AML) and squamous cell carcinoma (SCC). Improved transplant outcomes are modifying the natural history of Fanconi Anemia. Improved transplant survival, no radiation exposure, and almost no GVHD increases the importance of addressing later SCC even further. The investigators hypothesize that quercetin will prevent or delay the development of SCC and associated complications, there by ameliorating or delaying the need for potentially lethal treatment with chemotherapy and/or radiation therapy for the same.

Funding Source - FDA Office of Orphan Products Development (OOPD)

View Full Description

Full Description

Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure, variable congenital abnormalities and a predisposition to malignancy, particularly acute myeloid leukemia (AML) and squamous cell carcinoma (SCC). Currently, the only curative treatment option for the hematological complications of FA include hematopoietic cell transplantation (HCT). The investigators hypothesize that quercetin will prevent or delay the development of SCC and associated complications, there by ameliorating or delaying the need for potentially lethal treatment with chemotherapy and/or radiation therapy for the same.

This study is an open-label, single arm study. This study will enroll approximately 45 post-HCT patients with FA, and approximately 10 patients with FA without history of HCT. In both groups, patients with or without existing pre-malignant lesions or history of SCC will be allowed to participate, if they wish so and at the discretion of the PI. All patients will be treated with oral quercetin.

The investigators will determine the efficacy of Quercetin in reducing buccal micronuclei (a surrogate marker of DNA damage and susceptibility to squamous cell carcinoma due to genomic instability) in post-HCT patients with fanconi anemia (FA).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of FA
Able to take enteral medication
Patients ≥2 years

Exclusion Criteria:

Renal failure requiring dialysis
Total bilirubin >3 mg/dl and/or SGPT >200 at time of enrollment
Patients receiving digoxin therapy, who are unable to discontinue either treatment due to medical reasons
Patients who are pregnant or breastfeeding or are at risk of pregnancy or fathering a baby and are unable to use acceptable methods of birth control during the length of the study
Patients who have received quercetin supplementation or other antioxidants within the last 30 days
Patients receiving radiation therapy, chemotherapy or immunotherapy for treatment of SCC.

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 2

Estimated Enrollment:

55

Study ID:

NCT03476330

Recruitment Status:

Recruiting

Sponsor:

Children's Hospital Medical Center, Cincinnati

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Cincinnati Children's Hospital Medical Center
Cincinnati Ohio, 45229, United States More Info
Stephanie L Edwards, BSN, RN
Contact
513-636-9292
[email protected]
Parinda A Mehta, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 2

Estimated Enrollment:

55

Study ID:

NCT03476330

Recruitment Status:

Recruiting

Sponsor:


Children's Hospital Medical Center, Cincinnati

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.